Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
NCT01801358 · Array Biopharma, now a wholly owned subsidiary of Pfizer · PHASE1/PHASE2 · terminated · last registry update 2020-09-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was terminated for scientific reasons.” | – | Registry record, Array Biopharma, now a wholly owned subsidiary of Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PRKD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-17Results posted on the registry: Novartis Pharmaceuticals, Midostaurin (NCT01883362)
- 2020-12-19Phase 3 first posted: University Hospital Heidelberg, Quizartinib + Treatment according to Physician's Choice (NCT04676243)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, AEB071 (NCT01402440)
- 2020-12-17Also stopped (terminated): Novartis Pharmaceuticals, AEB071 + mycophenolic plus tacrolimus (NCT00555789)
- 2020-05-01Results posted on the registry: Brenda Cooper, MD, midostaurin + azacitidine (NCT01093573)
- 2020-01-09Also stopped (withdrawn): Novartis Pharmaceuticals, HDM201 + cytarabine (NCT03760445)
- 2019-11-22Phase 3 first posted: Gruppo Italiano Malattie EMatologiche dell'Adulto, Cytarabine + Daunorubicin (NCT04174612)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision